Harvard CRISPR pioneer Chad Cowan launches $78M stem cell play
One of the scientific founders of CRISPR Therapeutics AG (Nasdaq: CRSP) is embarking on a mission to solve a longstanding problem in stem cell therapy: ensuring that the body does not mount an immune response to the foreign cells.
He's got nearly $80 million to help him do it.
Chad Cowan, a Harvard Stem Cell Institute professor and a serial entrepreneur whose discoveries helped launch CRISPR Therapeutics as well as Sana Biotechnology, has found a way to "cloak" engineered stem cells. Now, he is…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news
More News: Biotechnology | Chad Health | Harvard | Health Management | Pharmaceuticals | Stem Cell Therapy | Stem Cells